IKT
HEALTHCAREInhibikase Therapeutics Inc
AI Insight
What's Moving IKT Today?
No stock-specific AI insight has been generated for IKT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.33$2.26
$1.87
Fundamentals
Market Cap$242M
P/E Ratio—
EPS$-0.44
Dividend Yield—
Dividend / Share—
ROE-40.2%
Profit Margin—
Debt / Equity—
Trading
Volume546K
Avg Volume (10D)—
Shares Outstanding132.0M
IKT News
15 articles- Phase 3 PAH trial IMPROVE-PAH spans 16 countries as orphan tag soughtStock Titan·May 13, 2026
- Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent ActivityYahoo Finance·May 12, 2026
- Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial HypertensionYahoo Finance·Apr 7, 2026
- Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
- Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent ActivityYahoo Finance·Mar 26, 2026
- Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ StocksYahoo Finance·Feb 22, 2026
- Sands Capital Opens $10 Million ServiceTitan PositionMotley Fool·Feb 18, 2026
- Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the companyYahoo Finance·Dec 8, 2025
- Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Nov 21, 2025
- Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Nov 20, 2025
- Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial HypertensionYahoo Finance·Nov 20, 2025
- Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent ActivityYahoo Finance·Nov 14, 2025
- Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy OfficerYahoo Finance·Aug 19, 2025
- Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent ActivityYahoo Finance·Aug 14, 2025
- Inhibikase Therapeutics Insiders Placed Bullish Bets Worth US$2.70mYahoo Finance·Jun 30, 2025
All 15 articles loaded
Price Data
Open$1.82
Previous Close$1.87
Day High$1.89
Day Low$1.81
52 Week High$2.26
52 Week Low$1.33
52-Week Range
$1.33$2.26
$1.87
Fundamentals
Market Cap$242M
P/E Ratio—
EPS$-0.44
Dividend Yield—
Dividend / Share—
ROE-40.2%
Profit Margin—
Debt / Equity—
Trading
Volume546K
Avg Volume (10D)—
Shares Outstanding132.0M
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—